Notícias e Atividades da Clarity Pharmaceuticals

Clarity Pharmaceuticals é uma das ...

• S&P/ASX200.

Clarity Pharmaceuticals é uma empresa listada sob o símbolo CU6 (AU).

Veja o organograma con seus 18 executivos principais

Biografias mais buscadas da Clarity Pharmaceuticals

• Michelle Parker, Chief Executive Officer
• Chris Roberts, Non-Executive Director
• Colin Biggin, Excecutive Director

Recentes movimentos de executivos em Clarity Pharmaceuticals

• Colin Biggin antes Director, Managing Director and Chief Executive Officer, agora é Excecutive Director  (Notícia publicada em 14 de outubro de 2024).
• Michelle Parker antes Director and Executive Vice President, Global Clinical Operations, foi promovido a Chief Executive Officer  (Notícia publicada em 14 de outubro de 2024).
• Robert Thomas, Lead Independent Director, se aposentou  (Notícia publicada em 26 de agosto de 2024).

Clique aqui para ver outras movimentos em Clarity Pharmaceuticals

Criar um alerta
para seguir os movimentos de executivos da Clarity Pharmaceuticals.

Clarity Pharmaceuticals possui 1.833 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Paul Meister - Chairman of the Board da Amneal Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Clarity Pharmaceuticals

• Clarity enters a Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Clarity’s COBRA study selected as a Top-Rated Oral Presentation at prestigious industry Annual Meeting - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Clarity promotes Michelle Parker to CEO - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Copper-67 SAR-bisPSMA updates - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Clarity launches $121 million fully underwritten equity raising - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Clarity successfully completes Placement and Institutional Entitlement Offer - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• SECuRE update: First participant treated in the last cohort of dose escalation - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• Clarity’s theranostic prostate cancer trial advances to multi-dose phase - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
• View more press releases Close

Redes sociais sobre Clarity Pharmaceuticals

• Clarity Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Clarity Pharmaceuticals na LinkedIn, Twitter e YouTube